Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety
|
|
- Amanda Hines
- 6 years ago
- Views:
Transcription
1 Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety
2 Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor, or any of its affiliated organizations.
3 Objectives Draft GVP Module IX (overview of changes) New terminology (EVDAS, ermr) MAH's obligations - access to EV, training, changes to current procedures
4 Introduction
5 Introduction Signal Management
6 Introduction
7 Introduction Benefit-risk management
8 MHRA GPvP Symposium 02 September 2016
9 Draft revision Module IX GVP First revision after 2012 implementation of new PV legislation Released for public consultation August 2016 Expected to be effective Q New elements introduced in the signal management process *Guideline on good pharmacovigilance practices (GVP). Module IX Signal management EMA/827661/2011 Rev 1* DRAFT for public consultation 04AUG2016
10 Draft revision Module IX GVP Revised definition and process for emerging safety issues, previously addressed in GVP Module VI Streamlined information on scientific aspects of signal management Statistical aspects now addressed in Addendum I Clarifications on terminology, roles and responsibilities, and processes Criteria for access by marketing authorisation holders to case narratives held in EudraVigilance Updated guidance on the periodicity of monitoring of EudraVigilance data Procedural options for signals validated by marketing authorisation holders *Guideline on good pharmacovigilance practices (GVP). Module IX Signal management EMA/827661/2011 Rev 1* DRAFT for public consultation 04AUG2016
11 Draft revision Module IX GVP Definitions Scientific aspects Steps in the process Timelines Communication *Guideline on good pharmacovigilance practices (GVP). Module IX Signal management EMA/827661/2011 Rev 1* DRAFT for public consultation 04AUG2016
12 GVP Module IX Signal management (rev1) IX.C.3.1 Emerging safety issues (definition) Module VI rev 1 - VI.C Module IX - rev1 IX.A.1 Terminology Events may occur, which do not fall within the definition of A safety issue considered by a marketing reportable valid ICSRs, and thus are not subject to the reporting authorisation holder in relation to an authorised requirements, even though they may lead to changes in the known medicinal product under its responsibility to risk-benefit balance of a medicinal product and/or impact on require urgent attention of the competent authority public health. Examples include: because of the potential major impact on the riskbenefit major safety findings from a newly completed non-clinical study; balance of the product and/or on patient or major safety concerns identified in the course of a noninterventional public health, that could warrant prompt regulatory post-authorisation study or of a clinical trial; action and communication to patients and signal of a possible teratogen effect or of significant hazard to healthcare professionals (see also GVP Module VI public health; and IX.C.3.1.). safety issues published in the scientific and medical literature; safety issues arising from the signal detection activity (see Module IX) or emerging from a new ICSR and which impact on the risk-benefit balance of the medicinal product and/or have implications for public health; safety issues related to the use outside the terms of the marketing authorisation; safety issues due to misinformation in the product information; marketing authorisation withdrawal, non-renewal, revocation or suspension outside the EU for safety-related reasons; urgent safety restrictions outside the EU; safety issues in relation to the supply of raw material; lack of supply of medicines. 06/03/
13 GVP Module IX Signal management (rev1) IX.C.3.1 Emerging safety issues (process) Module VI rev 1 - VI.C Reportable to : P-PV-emerging-safetyissue@ema.europa.eu Should be reported immediately when becoming aware of them. The document should indicate the points of concern and the actions proposed in relation to the marketing application/authorisation for the concerned medicinal product. Module IX. - rev 1 - C.3.1 Reportable to : P-PV-emerging-safety-issue@ema.europa.eu This should be reported within 2 working days of becoming aware of the issue. When notifying an emerging safety issue, the marketing authorisation holder should describe the safety concern, the source(s) of information, any planned or taken actions, and should provide any relevant documentation. In such instances, a standalone signal notification (see IX.C.3.4.) is not required. Upon being notified of an emerging safety issue, national competent authorities and/or the Agency as appropriate should promptly assess the urgency and potential impact of the issue and agree on appropriate next steps and the potential regulatory procedure to address the matter raised (see European Union Regulatory Incident Management Plan for Medicines for Human Use). In order to ensure its effectiveness, the system should not be saturated by the transmission of less urgent information. Marketing authorisation holders should only communicate as emerging safety issues those safety concerns which meet the definition provided in IX.A, i.e. whose urgency and seriousness cannot permit any delay in handling, for instance validated signals that cannot wait up to 30 days for confirmation by Member States. 06/03/
14 GVP Module IX Signal management (rev1) IX.A.1 Terminology Annex I Rev3 Signal Information arising from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action [IR 520/2012 Art 19(1)]. For the purpose of monitoring data in the EudraVigilance database, only signals related to an adverse reaction shall be considered [IR 520/2012 Art 19(1)]. For the purpose of Section 16.2 of the periodic benefitrisk evaluation report, signals relate to adverse effects (see Annex IV, ICH-E2C(R2) Guideline) Module IX - rev1 IX.A.1 Terminology Signal Information arising from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action [IR Art 19(1)]. New aspects of a known association may include changes in the frequency, duration, severity or outcome of the adverse event. For the purpose of monitoring data in the EudraVigilance database (also referred to as EudraVigilance ), only signals related to an adverse reaction shall be considered [IR Art 19(1)]. A signal often relates to all medicinal products containing the same active substance, including combination products. Certain signals may only be relevant for a particular medicinal product or in a specific indication, strength, pharmaceutical form or route of administration whereas some signals may apply to a whole class of medicinal products. 06/03/
15 GVP Module IX Signal management (rev1) IX.A.1 Terminology Amended definitions (vs GVP Annex I) - Signal management process - Signal validation New definitions (vs GVP Annex I) - Signal detection - Signal confirmation - Signal analysis and prioritisation by PRAC - Signal assessment by PRAC - Lead MS for signal assessment 06/03/
16 Draft revision Module IX GVP Definitions Scientific aspects Steps in the process Timelines Communication *Guideline on good pharmacovigilance practices (GVP). Module IX Signal management EMA/827661/2011 Rev 1* DRAFT for public consultation 04AUG2016
17 GVP Module IX Signal management (rev1) Addendum 1- Methodological Aspects of Signal Detection from Spontaneous Reports of Suspected Adverse Reactions 06/03/
18 GVP Module IX Signal management (rev1) Addendum 1 - General concept - Should allow routine signal detection - Based on the concept of Drug-Event Combinations (DECs) - Proposed statistical approach : Disproportionate reporting - Specific implementation in Eudravigilance is described in the Guidance «Screening for Adverse Drug Reactions in Eudravigilance» (available in Q4 2016) - The tools and their use will be described in separate user manuals (User Manual of the electronic Reaction Monitoring Report and EVDAS User Manual). 06/03/
19 GVP Module IX Signal management (rev1) Factors that may affect the performance of signal detection systems : * MedDRA hierarchy : Preferred Term (PT), has been shown to be a good choice in terms of sensitivity and positive predictive value, A subset of MedDRA terms judged to be important medical events (IMEs) is considered a useful tool in statistical signal detection, Other levels of MedDRA terms (HLT, SMQ) may be used for targeted monitoring of potential risks, Use of synonyms may be appropriate The definition of a synonym in this context is the pragmatic one that two PTs are considered synonyms if it is reasonable to suppose that a primary reporter of a suspected adverse reaction, presented with a single patient and without a specialist evaluation, would not necessarily be able to decide which term to use. 06/03/
20 GVP Module IX Signal management (rev1) Addendum 1 Methods aimed at specific groups of events Designated Medical Events It is recommended that these designated medical events (DME) are drawn to the attention of signal detection assessors irrespective of any other statistical methods used and that they are prioritised for clinical review. Serious events Due to their impact, serious events should be prioritised in Signal Detection. Complementary to the creation of a list of DMEs and in addition to the use of lists of IMEs, a simple approach to such prioritisation is to highlight new ICSRs in which a death is reported and to give separate counts of those ICSRs for each DEC. 06/03/
21 GVP Module IX Signal management (rev1) Addendum 1 Methods aimed at specific patients populations When ICSR databases are sufficiently large : - Paediatric populations - Geriatric populations Addendum 1 Methods aimed at underlying causal processes In addition to the description of the clinical manifestation of the suspected adverse reaction, ICSRs may include information on the potential causal mechanisms for the reaction. This applies to the situation of Abuse, misuse, overdose, medication error or occupational exposure. Thus, it is recommended that the numbers of ICSRs with the respective MedDRA codes should be displayed for each DEC in signal detection listings. 06/03/
22 Draft revision Module IX GVP Definitions Scientific aspects Steps in the process Timelines Communication *Guideline on good pharmacovigilance practices (GVP). Module IX Signal management EMA/827661/2011 Rev 1* DRAFT for public consultation 04AUG2016
23 GVP Module IX Signal management (rev1) IX.C.2.1 Principles for access (Eudravigilance Data) Prior to requesting access to case narratives, the following criteria should be met: The review of the electronic reaction monitoring report suggests a signal (see IX.A.); To the best of the marketing authorisation holder s knowledge, the signal is not addressed in the product information of any medicinal product authorised in the EU with the concerned active substance (see also IX.C.3.4.); Based on the information published on the European medicines webportal (see IX.C.8.), the signal was not recently addressed by (a) competent authority(ies) of (a) Member State(s) or by PRAC See European Medicines Agency Policy on Access to EudraVigilance data for Medicinal Products for Human Use EMA/759287/2009 rev 2 of 17 Dec /03/
24 GVP Module IX Signal management (rev1) IX.C.2.2 Periodicity of monitoring The appropriate frequency of monitoring of EudraVigilance data may vary with the accumulation of knowledge on the risk profile of a given active substance or medicinal product, taking into account, for example: time since first authorisation; patient exposure; potential risks and missing information documented in the RMP; PSUR submission frequency; any safety concern of interest in specific situations (e.g. vaccination campaigns). Thus : - A 2 weeks interval for products on additional monitoring list unless the sole reason for inclusion on the list is the request of a post-authorisation safety study (PASS), - A monthly monitoring of EudraVigilance data is routinely applied by the Agency for other active substances, - It is recommended that the interval between reviews of EudraVigilance data should not exceed 6 months. - Each organisation should document the frequency of their monitoring of 06/03/ EudraVigilance data
25 GVP Module IX Signal management (rev1) The evaluation of the evidence supporting a signal may involve several rounds of expert discussions and different levels of decisionmaking, within individual organisations. This may result in various decisions, such as: closing the signal, when the available data do not support a causal relationship (the signal may be re-opened at a later stage if new evidence arises) or when there is sufficient information on the association in the product information; monitoring the signal by reviewing new information from ICSRs or the scientific literature at appropriate time intervals to determine whether the new data are supportive of a causal relationship; proposing actions such as changes to the product information by means of a variation, if there is sufficient evidence of a causal relationship. 06/03/
26 GVP Module IX Signal management (rev1) IX.B.4 Signal prioritisation 2 new concepts added to help prioritisation : the expected extent of the regulatory intervention (e.g. addition of adverse reactions, warnings, contraindications, additional risk minimisation measures, suspension, revocation); whether the signal is likely to apply to other substances of the same class of medicinal products. 06/03/
27 GVP Module IX Signal management (rev1) IX.C.1 Roles and responsibilities 06/03/
28 GVP Module IX Signal management (rev1) IX.C.1 Roles and responsibilities PRAC List of signals 06/03/
29 New terminology EudraVigilance Data Analysis System (EVDAS) Module allowing data mining in Eudravigilance Electronic reaction monitoring report (ermr) Output from EVDAS European Pharmacovigilance Issues Tracking Tool (EPITT) Signal tracker
30 New terminology 9.jsp&mid=WC0b01ac05800b6f03
31 New terminology
32 New terminology
33 New terminology
34 New terminology 3. Drug info : this worksheet is automatically updated every 6 months. It is populated with the most used information related to a given active substance,
35 New terminology
36 MAH s obligations Access to Eudravigilance (new systems) Availability of dedicated resources Appropriate training of people involved in signal management 4200 MAHs (see EMA Annual activity report 2015) Adaptation of internal procedures Adaptation of SDEA with partners
37 MAH s obligations
38 Additonal resources The following documents provide additional guidance relevant to signal management: Report of CIOMS Working Group VIII on Practical Aspects of Signal Detection in Pharmacovigilance SCOPE Work Package 5 Signal Management - Best Practice Guidance EMA Questions & Answers on Signal Management Screening for Adverse Drug Reactions in EudraVigilance (Dec2016) IMI-PROTECT - Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (Sep2016) WEB-RADR - use of mobile technologies in pharmacovigilance to Recognise Adverse Drug Reactions (RADR).
39 Take home message Pharmacovigilance legislations are continuously evolving globally New methodologies are adopted Signal management has a great impact on continuous benefit-risk management Need for a cross-functional approach Robust process and documentation need to be in place Heavily scrutinized in audits/inspections
40
Guideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 9 October 2017 EMA/827661/2011 Rev 1* - Track-change version following public consultation 3 4 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationSignal Management in the EU and future extended access to EudraVigilance for industry
Signal Management in the EU and future extended access to EudraVigilance for industry 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Georgy Genov 7 December 2015 Head of Signal
More informationUpdate on preparation for Signal Management
Update on preparation for Signal Management 7 th industry stakeholder platform operation of EU PV legislation Presented by Georgy Genov on 4 April 2016 Head of Signal Management - Pharmacovigilance Department
More informationFeedback on EudraVigilance & new functionalities
Feedback on EudraVigilance & new functionalities 14th industry stakeholder platform operation of EU pharmacovigilance Anja van Haren (MEB), Sabine Brosch (EMA) and Francois Domergue (EMA) An agency of
More informationGVP Module IX: Signal Management
27 February 2012 4 th Stakeholders Forum Presented by: Agnieszka Szmigiel Pharmacovigilance and Risk Management Sector, EMA An agency of the European Union Topics Scope of Module IX Signal Management (SM)
More informationScreening for adverse reactions in EudraVigilance
Screening for adverse reactions in EudraVigilance Basel Biometric Society meeting, 29 th November 2016 Gianmario Candore Data Standardisation and Analytics (EMA) An agency of the European Union Disclaimer
More informationPharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri
Pharmacovigilance Training session for patients and consumers involved in EMA activities, 25 November 2014 Presented by: Priya Bahri An agency of the European Union 2 Pharmacovigilance - the science concerned
More informationEudraVigilance auditable requirement project
22 November 2017 EMA/835422/2016 Information Management Division EudraVigilance training plan (version 5) Project Maintenance Group 1 consultation 11 December 2015 Eudravigilance Expert Working Group consultation
More informationGood Vigilance Practice Module VI
Good Vigilance Practice Module VI Management and reporting of adverse reactions to medicinal products Stakeholders forum 27th February 2012 Gilles Touraille Signal Detection and Data Analysis Pharmacovigilance
More informationImplementing the New Pharmacovigilance Legislation
Implementing the New Pharmacovigilance Legislation Irish Medicines Board, Pharmacovigilance Information Day, Dec 2011 Dr. Almath Spooner Vigilance Assessment Manager, Human Products Monitoring Department
More informationRecent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility
Recent developments in Pharmacovigilance from the Regulator s Perspective In strategy, competence, quality and flexibility Pharmacovigilance Regulatory Affairs Operations Medical Writing & toxicology Recent
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816292/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report Draft finalised by the Agency in collaboration with Member
More informationGuidelines on good pharmacovigilance practices (GVP)
15 September 2014 EMA/475236/2014 Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision 1 of module III on pharmacovigilance inspections and of module
More informationImplementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories
Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories Agenda PSMF PSURs Solicited sources RMPs Inspections Signal detection
More informationGuide for Marketing Authorisation Holders on Direct Healthcare Professional Communications
Guide for Marketing Authorisation Holders on Direct Healthcare Professional Communications 1 INTRODUCTION A Direct Healthcare Professional Communication (DHPC) aims to promote safe and effective use of
More informationQ & A on PSUSA: Guidance document for assessors
31 October 2017 EMA/518909/2016 Human Medicines Evaluation Division Q & A on PSUSA: Guidance document for assessors Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA),
More informationNew EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More informationGuidelines on good pharmacovigilance practices (GVP)
7 June 2013 EMA/321625/2013 Patient Health Protection Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with launch of public consultation of module VI revision
More informationEudraVigilance: Preparing for Change
EudraVigilance: Preparing for Change EudraVigilance Auditable Requirement project 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Francois Domergue, Data Standardisation and
More informationFormat and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)
Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) First Stakeholders Forum on the implementation of the new Pharmacovigilance legislation,
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationUK Standards for Pharmacovigilance Departments 2015
UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires
More informationVM-ID: MU101_20_001e_WL - Wegleitung_HD - Hilfsdokument / V3.0 / dst / er / / 6
Contents 1 Abbreviations... 1 2 Requirements for signal reports... 2 3 Introduction... 2 4 Objective... 2 5 Scope... 2 6 Company signals (signals evaluated by the MAH)... 2 6.1 Signals involving a serious
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/813938/2011 Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies Draft finalised by the Agency in collaboration with Member States and submitted
More informationPharmacovigilance information for pharmaceutical companies
Pharmacovigilance information for pharmaceutical companies Electronic transmission of individual case safety reports (ICSRs) with ANSM (French National Agency for the safety of Medicines and Health Products)
More informationSignal Detection Quantitative Analysis of Safety Data. Dr. Yusuf Tanrikulu Basel, 29th November 2016
Signal Detection Quantitative Analysis of Safety Data Dr. Yusuf Tanrikulu Basel, 29th November 2016 Contents Regulatory background Goals of signal detection Data sources Methods Recent developments 2 Regulatory
More informationEMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)
7 November 2011 EMA/863255/2011 EMA Comments on Implementing for Pharmacovigilance (PCIM/11/01) The Agency welcomes the public consultation on the Commission concept paper on the implementing measures
More informationENCePP Plenary: New Pharmacovigilance legislation
ENCePP Plenary: New Pharmacovigilance legislation 18 November 2010 Peter Arlett Head of Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk 1. New pharmacovigilance legislation:
More informationPHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use
PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationGuideline on good pharmacovigilance practices (GVP)
8 September 2014 EMA/873138/2011 Rev 1* (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products (Rev 1) Date
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationPharmacovigilance Inspection Metrics Report
Pharmacovigilance Inspection Metrics Report April 2016 - March 2017 1. Introduction During the period 01 April 2016 to 31 March 2017, the GPvP Inspectorate conducted 36 inspections of marketing authorisation
More informationNew pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
More informationAdjusting to Effectively Meet the New European Union Pharmacovigilance Requirements
Adjusting to Effectively Meet the New European Union Pharmacovigilance Requirements Deirdre McCarthy Michelle Bulliard GRP Webinar 31 January 2013 Copyright 2013 Quintiles Your Presenters Deirdre McCarthy
More informationPharmacovigilance information for pharmaceutical companies
Pharmacovigilance information for pharmaceutical companies Electronic transmission of individual case safety reports (ICSRs) with ANSM (French National Agency for the safety of Medicines and Health Products)
More informationRegulatory Aspects of Pharmacovigilance
Regulatory Aspects of Pharmacovigilance Deirdre Mc Carthy Pia Caduff-Janosa Training Course Uppsala 2012 Agenda Risk based approach to spontaneous reporting (incl clinical trials) -> Pia Caduff-Janosa
More informationThe EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines
The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines Health care uncertainty assessment workshop Session 3: The challenges of health
More informationGuidelines on good pharmacovigilance practices (GVP)
12 April 2013 EMA/131811/2013 Patient Health Protection Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision of module II, launch of public consultation
More informationVOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use
VOLUME 9 - PHARMACOVIGILANCE Medicinal Products for Human and Veterinary Use FOREWORD Directive 75/319/EEC as amended by Commission Directive 2000/38/EC of 5 th June 2000 and Directive 81/851/EEC as amended
More informationPilot of MAH signal detection in EudraVigilance
Pilot of MAH signal detection in EudraVigilance 13 th Industry Stakeholder Platform operation of EU pharmacovigilance Presented by Julie Durand Signal & Incident Management Service - Pharmacovigilance
More informationEU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP
EU Pharmacovigilance Legislation - One Year Later Sarah Daniels; Senior Partner TranScrip Partners LLP Since July 2012 we have officially been operating under EU legislation Directive 2010/84/EU amending
More informationGuidelines for Pharmacovigilance Inspections
PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT
More informationModule VIII- Post-authorisation safety studies
Good Vigilance Practice Module VIII- Post-authorisation safety studies 4th Stakeholder Forum Xavier Kurz An agency of the European Union Post-authorisation safety study Any study relating to an authorised
More informationAgenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)
EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) 726/2004 Agenda item 4.1 Draft proposal - Notifications
More informationPSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we
More informationEphMRA Adverse Event Reporting Guidelines 2016
EphMRA Adverse Event Reporting Guidelines 2016 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationEudraVigilance access policy for medicines for human use
23 August 2011 EMA/759287/2009 corr. Patient Health Protection Draft agreed by the EudraVigilance Expert Working Group December 2007 Consultation with the EudraVigilance Steering Committee February 2008
More informationApplies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).
Work instructions Title: Training for signal management leads Applies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).
More informationOverview of the new pharmacovigilance legislation
Overview of the new pharmacovigilance legislation SME workshop: 19 April 2012 Dr Peter Arlett Head, Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk: New legislation
More informationGVP Module X - additional monitoring of medicines
GVP Module X - additional monitoring of medicines 6 th Stakeholders forum on the implementation of the new pharmacovigilance legislation Mick Foy, Group Manager - MHRA An agency of the European Union Contents
More informationWissenswertes aus dem Bereich PHV
Wissenswertes aus dem Bereich PHV Dr. Susanne Wolf Dept. Assessment Pharmacovigilance AGES-Gespräche Vienna, 15.09.2016 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH www.ages.at
More informationGuideline on good pharmacovigilance practices (GVP)
15 April 2014 EMA/876333/2011 Rev 3* (superseded version) Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 3) Date for coming into effect of first version 2 July 2012 Date
More informationGood Pharmacovigilance Practice Tunisian guidelines
Good Pharmacovigilance Practice Tunisian guidelines Introduction Arab ministers of health came to a common decree (number 7) in their 37th regular meeting in March 2012. The Higher Technical Committee
More informationDoc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034
More informationPeriodic Safety Update Reports. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017
Periodic Safety Update Reports Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 Periodic Safety Update Reports - Evolution - Definition - Objective - Frequency and timing - EU vs USA and other non
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/876333/2011 Rev 4* Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4) Date for coming into effect of first version 2 July 2012 Date for coming into effect
More informationEudraVigilance NEU. Mag. pharm. Katharina Weber. BASG/AGES Medizinmarktaufsicht Institut Überwachung - Abteilung Blut, Gewebe und Vigilanz
EudraVigilance NEU Mag. pharm. Katharina Weber BASG/AGES Medizinmarktaufsicht Institut Überwachung - Abteilung Blut, Gewebe und Vigilanz AGENDA EudraVigilance neu Legal Requirements Process Change Management
More informationII.B.4. Information to be contained in the PSMF/ PSSF
II.B.4. Information to be contained in the PSMF/ PSSF No. PSMF/ PSSF section Remarks Cover Page: 1- The unique number (Revision No.) 2- The name of the MAH, QPPV or LSR (including third party). 3- The
More informationEudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables
24 May 2018 EMA/349760/2018 Information Management Division EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables Pharmacovigilance
More informationScreening for adverse reactions in EudraVigilance
19 December 2016 EMA/849944/2016 Inspections, Human Medicines, Pharmacovigilance and Committees Division Table of contents 1. Introduction... 3 2. Scope... 4 3. An integrated approach to signal detection...
More informationPharmacovigilance. Maia Uusküla
Pharmacovigilance Maia Uusküla 27.10.2012 PhV activities - Local ADR reports (collection, assessment) - Encouragement of HCPs to report ADRs - Increase knowledge about ADRs - benefit-risk assessment -Assessment
More informationSafety Measures in the new Pharmacovigilance System
Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation
More informationMHRA GPvP Symposium Summary 6 November 2015 Novotel Hotel, London
MHRA GPvP Symposium Summary 6 November 2015 Novotel Hotel, London Contents MHRA Symposium... page 03 Common Inspection Findings...page 04 Self-Governance...pages 05-06 SIGNAL Management...pages 07-08 RSI-
More informationFunctioning of the PRAC
Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment
More informationFrameworks for use of social media in pharmacovigilance. Sabine Brosch, European Medicines Agency
Frameworks for use of social media in pharmacovigilance Sabine Brosch, European Medicines Agency Frameworks for use of social media in pharmacovigilance Objectives Assess the current regulatory framework
More informationEudraVigilance auditable requirement project: ADRreports.eu portal update
EudraVigilance auditable requirement project: ADRreports.eu portal update Patients and Consumers Working Party 30 th November 2016 Francois Domergue, Business project manager An agency of the European
More informationSignal detection experience to date
EMA / IFAH-Europe Info Day Presented by Jos Olaerts on 13 March 2015 An agency of the European Union What is it? How is it done? Does it work? What s next? 1 Definition of signal detection Council for
More informationKLH-21 version 7 With effect from the date of issue (effective date 20th July 2018), this guideline supersedes guideline KLH-21, version 6.
KLH-21 version 7 Reporting Adverse Reactions to Medicinal Products for Human Use in a Clinical Trial and to Medicinal Products without Marketing Authorisation The guideline is being issued on the basis
More informationIndustry perspective: Non-prescription medicines
EMA 7 th Stakeholders forum on the implementation of the new pharmacovigilance legislation 27 September 2013 Industry perspective: Non-prescription medicines Introduction Perfect timing for a review Comprehensive
More informationRe: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance
07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing
More informationQuestions and answers on preparation, management and assessment of periodic safety update reports (PSURs)
21 June 2018 EMA/CVMP/PhVWP/126661/2009-Rev.4-corr. Committee for Medicinal Products for Veterinary Use Questions and answers on preparation, management and assessment of periodic safety update reports
More informationConsultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete.
Association Européenne des Spécialités Pharmaceutiques Grand Public Association of the European Self-Medication Industry Europäischer Verband der Arzneimittel-Hersteller AESGP Position Paper on the European
More informationStakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency
New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationCMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS
CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS 1. INTRODUCTION CMDh/322/2014/Rev.0 November 2014 This Standard Operating Procedure
More informationUpdate on SCOPE - Strengthening Collaborations to. Operate Pharmacovigilance in Europe
Update on SCOPE - Strengthening Collaborations to Operate Pharmacovigilance in Europe Background Review Of The EU System 2 Pharmacovigilance Legislation 2012: EU Pharmacovigilance legislation Directive
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationNIS Considerations - Bulgaria
NIS Considerations - Bulgaria An overview of the considerations when conducting Noninterventional Studies in Bulgaria Stuart McCully CHCUK Ltd NIS-C-BG-2014 1 Table of Contents Disclaimer 5 Copyright 5
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted
More informationEUROPEAN PHARMACEUTICAL MARKET RESEARCH ASSOCIATION (EphMRA) RESPONSE TO
EUROPEAN PHARMACEUTICAL MARKET RESEARCH ASSOCIATION (EphMRA) RESPONSE TO IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS
FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013
More informationGuidance on format of the risk management plan (RMP) in the EU part VII: Annexes
7 November 2012 EMA/716217/2012 Patient Health Protection Guidance on format of the risk management plan (RMP) in the EU part VII: Annexes Active substance Product(s) concerned (brand name(s)): MAH/Applicant
More informationThree years of the Pharmacovigilance Risk Assessment Committee Where are we now?
Three years of the Pharmacovigilance Risk Assessment Committee Where are we now? June M Raine Chair, PRAC MEB College Day Workshop 3 rd June 2015 An agency of the European Union The Pharmacovigilance Risk
More informationThe new Pharmacovigilance legislation and implementation planning
The new Pharmacovigilance legislation and implementation planning Second Stakeholders meeting 17 June 2011 European Medicines Agency, London, UK Presented by: Franck Diafouka Manager, Pharmacovigilance
More informationThe PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member
The PRAC Roles and challenges Focus on RMPs and RMAs Prof. Jean-Michel Dogné Head of the Department of Pharmacy PRAC effective member Rue de Bruxelles, 61 B-5000 Namur, Belgium Phone: 0032 (0)81 724289
More informationPublication of Risk Management Plan (RMP) summaries:
Publication of Risk Management Plan (RMP) summaries: Analysis of the experience of the 1-year pilot phase Presented by Juan Garcia Burgos and Caroline Voltz An agency of the European Union Outline Background
More informationPharmacovigilance Legislation: The Impact of What Is Happening in Europe
Miranda Z. Dollen, BSc (Hons) 1 Abstract Pharmaceutical companies, regulatory agencies, and contract service organizations are managing substantial and ongoing changes to pharmacovigilance legislation
More informationSCOPE Work Package 5 Survey Report
SCOPE Work Package 5 Survey Report Topic: Signal Management Authors: Alexandra Pacurariu Anja van Haren Anna-Lena Berggren Birgitta Grundmark Helle Harder Mona Vestergaard Laursen Paul Barrow Phil Tregunno
More information